Kevin Gordon Biography and Net Worth

Director of Progyny


Kevin Gordon has served as a member of our board of directors since October 2019. Mr. Gordon has also served as an advisor to 3i Group’s North American healthcare portfolio companies since January 2022, including currently as a director of privately held Q Holdco Limited, Sanisure, and Cirtec Medical Corp. Mr. Gordon served on the board of directors of Veracyte, Inc., a genomic diagnostics company, from December 2016 until June 2022. From January 2018 until March 2019, he was the President and Chief Financial Officer of Liquidia Technologies Inc., a clinical biopharmaceutical company. Mr. Gordon served as Executive Vice President and Chief Operating Officer of Quintiles Transnational Holdings Inc., or Quintiles, a research, clinical trial and pharmaceutical consulting company, from October 2015 until its merger with IMS Health Holdings, Inc. (forming IQVIA Holdings, Inc.) in October 2016. Prior to that, he was the Executive Vice President and Chief Financial Officer of Quintiles from July 2010 until December 2015. Mr. Gordon served as Executive Vice President and Chief Financial Officer of Teleflex Incorporated, a medical device company, from March 2007 until January 2010 and he held various senior corporate development positions there from 1997 to 2007. Prior thereto he held various senior positions, including Chief Financial Officer, at Package Machinery Company and senior manager and other positions at KPMG LLP. Mr. Gordon holds a B.S. in Accounting from the University of Connecticut. We believe that Mr. Gordon is qualified to serve on our board of directors because of his extensive accounting experience and leadership experience in healthcare companies.

What is Kevin K. Gordon's net worth?

The estimated net worth of Kevin K. Gordon is at least $315,722.16 as of December 11th, 2023. Mr. Gordon owns 9,854 shares of Progyny stock worth more than $315,722 as of April 27th. This net worth estimate does not reflect any other investments that Mr. Gordon may own. Learn More about Kevin K. Gordon's net worth.

How do I contact Kevin K. Gordon?

The corporate mailing address for Mr. Gordon and other Progyny executives is 1359 BROADWAY, NEW YORK NY, 10018. Progyny can also be reached via phone at 212-888-3124 and via email at [email protected]. Learn More on Kevin K. Gordon's contact information.

Has Kevin K. Gordon been buying or selling shares of Progyny?

Kevin K. Gordon has not been actively trading shares of Progyny in the last ninety days. Most recently, Kevin K. Gordon sold 2,500 shares of the business's stock in a transaction on Monday, December 11th. The shares were sold at an average price of $35.93, for a transaction totalling $89,825.00. Following the completion of the sale, the director now directly owns 9,854 shares of the company's stock, valued at $354,054.22. Learn More on Kevin K. Gordon's trading history.

Who are Progyny's active insiders?

Progyny's insider roster includes Peter Anevski (COO), Jennifer Bealer (EVP), Kevin Gordon (Director), Lisa Greenbaum (EVP), Mark Livingston (CEO), Norman Payson (Director), David Schlanger (CEO), Cheryl Scott (Director), and Michael Sturmer (President). Learn More on Progyny's active insiders.

Are insiders buying or selling shares of Progyny?

In the last twelve months, insiders at the sold shares 36 times. They sold a total of 3,771,931 shares worth more than $151,880,735.89. The most recent insider tranaction occured on April, 1st when Chairman David J Schlanger sold 1,000 shares worth more than $37,520.00. Insiders at Progyny own 12.3% of the company. Learn More about insider trades at Progyny.

Information on this page was last updated on 4/1/2024.

Kevin K. Gordon Insider Trading History at Progyny

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/11/2023Sell2,500$35.93$89,825.009,854View SEC Filing Icon  
5/24/2023Sell1,410$38.24$53,918.4012,354View SEC Filing Icon  
See Full Table

Kevin K. Gordon Buying and Selling Activity at Progyny

This chart shows Kevin K Gordon's buying and selling at Progyny by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Progyny Company Overview

Progyny logo
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Read More

Today's Range

Now: $32.04
Low: $31.99
High: $32.70

50 Day Range

MA: $35.84
Low: $31.88
High: $40.79

2 Week Range

Now: $32.04
Low: $29.44
High: $44.95

Volume

583,458 shs

Average Volume

653,672 shs

Market Capitalization

$3.08 billion

P/E Ratio

51.68

Dividend Yield

N/A

Beta

1.48